Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial

BMJ Open

Volumn 5, Issue 11, 2015, Pages

  Sontrop, Jessica M ^a,b   Huang, Shi Han ^a   Garg, Amit X ^a,b   Moist, Louise ^a,b   House, Andrew A ^a   Gallo, Kerri ^a   Clark, William F ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; GLYCOPEPTIDE;

AGED; BLOOD; CANADA; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRINKING; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOMARKERS; CANADA; DRINKING; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 85016754511     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/BMJOPEN-2015-008634     Document Type: Article

References (53)

1. Bouby N, Fernandes S. Mild dehydration, vasopressin and the kidney: animal and human studies. Eur J Clin Nutr 2003;57(Suppl 2):S39-46.
2. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-19.
3. Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 2014;99:4656-63.
4. Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012;27:4131-7.
5. Boertien WE, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013;61:420-9.
6. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102-8.
7. Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558-64.
8. Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-8.
9. Yalta K, Yalta T, Sivri N, et al. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013;167:1750-9.
10. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction. Circulation 2007;115:2103-10.
11. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096-106.
12. Velho G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 2013;36:3639-45.
13. Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-9.
14. Bouby N, Bachmann S, Bichet D, et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol Ren Physiol 1990;258:F973.
15. Sugiura T, Yamauchi A, Kitamura H, et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-β. Kidney Int 1999;55:1800-10.
16. Clark WF, Sontrop JM, Macnab JJ, et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011;6:2634-41.
17. Sontrop JM, Dixon SN, Garg AX, et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol 2013;37:434-42.
18. Strippoli GF, Craig JC, Rochtchina E, et al. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 2011;16:326-34.
19. Clark WF, Sontrop JM, Huang S-H, et al. The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open 2013;3:e003666.
20. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 2005;4:287-91.
21. Moore CG, Carter RE, Nietert PJ, et al. Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci 2011;4:332-7.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J kidney Dis 2002;39(2 Suppl 1):S1-S266.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
24. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
25. Sedgwick P. Randomised controlled trials: balance in baseline characteristics. BMJ 2014;349:g5721.
26. Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009;88:561-7.
27. Zittema D, van den Berg E, Meijer E, et al. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2014;9:1553-62.
28. Meijer E, Bakker SJ, Halbesma N, et al. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010;77:29-36.
29. Meijer E, Casteleijn NF. Riding the waves: evidence for a beneficial effect of increased water intake in autosomal dominant polycystic kidney disease patients? Nephrol Dial Transplant 2014;29:1615-17.
30. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013;9:223-39.
31. Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17:2220-7.
32. Wang X, Gattone V, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16:846-51.
33. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18.
34. Bankir L, Bichet DG, Bouby N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Ren Physiol 2010;299:F917-28.
35. Enhörning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes(Lond) 2012;37:598-603.
36. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987;82:1213-19.
37. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118:410-21.
38. Wong L. Vasopressin V2 receptor antagonists. Cardiovasc Res 2001;51:391-402.
39. Enhörning S, Leosdottir M, Wallström P, et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr 2009;89:400-6.
40. Plischke M, Kohl M, Bankir L, et al. Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort-a possible titration target? PLoS ONE 2014;9:e93226.
41. Bankir L, Bichet DG. Polycystic kidney disease: an early urea-selective urine-concentrating defect in ADPKD. Nat Rev Nephrol 2012;8:437-9.
42. Johnson RJ, Rodriguez-Iturbe B, Roncal-Jimenez C, et al. Hyperosmolarity drives hypertension and CKD-water and salt revisited. Nat Rev Nephrol 2014;10:415-20.
43. Bardoux P, Bichet DG, Martin H, et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003;18:497-506.
44. Cirillo M. Determinants of kidney dysfunction: is vasopressin a new player in the arena? Epidemiology of atherosclerotic renal artery stenosis as a mirror. Kidney Int 2010;77:5-6.
45. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens 2010;19:499-504.
46. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010;16(Suppl 1):S37-44.
47. Fenske W, Wanner C, Allolio B, et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 2011;22:782-90.
48. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-32.
49. Palmer SC, Wong G, Iff S, et al. Fluid intake and all-cause mortality, cardiovascular mortality, and kidney function: a population-based longitudinal cohort study. Nephrol Dial Transplant 2014;29:1377-84.
50. Szinnai G, Mörgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007;92:3973-8.
51. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-8.
52. Yun AJ, Lee PY, Bazar KA. Clinical benefits of hydration and volume expansion in a wide range of illnesses may be attributable to reduction of sympatho-vagal ratio. Med Hypotheses 2005;64:646-50.
53. Wang CJ, Grantham JJ, Wetmore JB. The medicinal use of water in renal disease. Kidney Int 2013;84:45-53.